Roche Holding AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 225
- Registration Number
- NCT00002247
- Locations
- ๐บ๐ธ
Mount Zion Med Ctr, San Francisco, California, United States
๐บ๐ธDr Dorothy Friedberg, New York, New York, United States
๐บ๐ธGeorgetown Univ Med Ctr, Washington, District of Columbia, United States
A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT00002251
- Locations
- ๐บ๐ธ
Davies Med Ctr, San Francisco, California, United States
๐บ๐ธGeorgetown Univ Med Ctr, Washington, District of Columbia, United States
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT00002162
- Locations
- ๐บ๐ธ
UCD Med Ctr, Sacramento, California, United States
๐บ๐ธRush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
๐บ๐ธUCSD Treatment Ctr, San Diego, California, United States
An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002135
- Locations
- ๐บ๐ธ
Roche Global Development - Palo Alto, Palo Alto, California, United States
Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002024
- Locations
- ๐บ๐ธ
Roche Global Development - Palo Alto, Palo Alto, California, United States
A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT00002367
- Locations
- ๐บ๐ธ
AIDS Healthcare Foundation Labs, Los Angeles, California, United States
๐บ๐ธUrgent Care Ctr / North Broward Hosp District, Fort Lauderdale, Florida, United States
The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002299
- Locations
- ๐บ๐ธ
UCI Med Ctr, Orange, California, United States
๐บ๐ธUniv of California / San Diego Treatment Ctr, San Diego, California, United States
๐บ๐ธUSC, Los Angeles, California, United States
Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002081
- Locations
- ๐บ๐ธ
ddC Coordinating Ctr, Wellesley Hills, Massachusetts, United States
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 700
- Registration Number
- NCT00002095
- Locations
- ๐บ๐ธ
Kraus - Beer Med Group, Los Angeles, California, United States
๐บ๐ธBeth Israel Hosp, Boston, Massachusetts, United States
๐บ๐ธUCSD, San Diego, California, United States
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT00002143
- Locations
- ๐บ๐ธ
Beth Israel Med Ctr, New York, New York, United States